P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

類似資料

• P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
  著者:: Barbara Eichhorst, 等
  出版事項: (2023-08-01)
• Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
  著者:: Mazyar Shadman, 等
  出版事項: (2025-08-01)
• Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China
  著者:: Ying Liu, 等
  出版事項: (2026-03-01)
• Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL
  著者:: John N. Allan, 等
  出版事項: (2025-08-01)
• Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
  著者:: Constantine S. Tam, 等
  出版事項: (2026-02-01)